Health Care Analysis on Myocardial Revascularization in Patients With Chronic Coronary Heart Disease (CHD)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04599361

Acronym

REVASK

Enrollment

385

Registered

2020-10-22

Start date

2021-04-01

Completion date

2022-12-31

Last updated

2023-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Keywords

Chronic coronary heart disease, myocardial revascularization, heart team, decision making, cardiology, heart surgery

Brief summary

Myocardial infarction and chronic coronary heart disease (cCHD) are the most frequent causes of death in Germany. Treatment options include widening of the narrowed / blocked coronary vessel via catheter and stent or bypass surgery in which the narrowed vessel sites are bridged. The German National Disease Management Guideline on cCHD helps doctors to decide which treatment is most appropriate for the severity of vascular damage and possible concomitant diseases of the patient. Nevertheless, there are other factors determining treatment decision. For example, the equipment or preferences of the hospital or department in which patients are admitted, play a role in the decision. The aim of the REVASK project is to investigate whether and to what extent the collaboration of cardiology and heart surgery specialists in so-called heart teams influences the decision on therapy. For this purpose, doctors and patients will be interviewed about how the treatment decision was made and how satisfied both sides are with the outcome of the treatment and the decision. In addition, claims data from several German health insurance companies (Techniker, BARMER, Betriebs- und Innungskrankenkassen) will be analyzed. Treatment data, which is documented as usual by the treating medical staff and passed on to the health insurance companies for accounting purposes, is used. Furthermore, treatment data recorded in the registers of the professional societies is analyzed.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 105 Years

Healthy volunteers

Inclusion criteria

* with chronic coronary heart disease * and 2- or 3-vessel or main-vessel disease * who are being treated at one of the recruitment sites * with a promptly planned intervention for myocardial revascularization * who are insured with pre-specified German health insurance companies (BARMER or TK)

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Guideline compliance	2 years	Guidelines-compliant therapy in patients with chronic CHD (2- or 3-vessel or main vessel disease) according to German National Disease Management Guideline on chronic coronary heart disease

Secondary

Measure	Time frame	Description
Heart teams	2 years	Frequency and quality of heart teams
Patient participation	2 years	extent of patient participation in the decision making process
Decision making process	2 years	importance of clinical parameters in the decision-making process (e.g. syntax scores, iFR, FFR)

Countries

Germany

Outcome results